A study testing whether a GLP-1 medicine, semaglutide, can help people with type 1 diabetes lower blood sugar.

Recruiting now. Registry record last updated December 18, 2025.

Who can join: Ages 12 to 50, have type 1 diabetes, BMI 18+.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor Vanderbilt University Medical CenterDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 24

What this study is for

Primary condition: Type 1 Diabetes.

Full scientific study title: GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab.

Who can join

Age12 to 50SexAnyBMI18 or higher

Ages 12 to 50, have type 1 diabetes, BMI 18+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Age: 12-50 years
BMI: 18-31 kg/m2 (adults) or 5-95th %ile (pediatric)
Stage 2 T1DM (i.e., ≥ 2 islet auto-antibodies and:
fasting glucose ≥ 100 mg/dL and \< 126 mg/dL OR
2-hr OGTT /MMTT ≥ 140 mg/dL and \< 200 mg/dL OR

Key exclusion criteria

Comorbidities:
SBP \> 140 mmHg and DBP \> 100 mmHg
eGFR by MDRD equation of \< 60 mL/min/1.73m2
AST or ALT \> 2.5 times ULN
Family history of medullary thyroid carcinoma

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Tennessee1 site

Vanderbilt University Medical Center
Nashville, Tennessee
Daniel J Moore, MD, PhD(615) 322- 7427metabolism@vumc.org

Follow this trial

We email you if NCT06338553 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: June 12, 2024. Expected completion: March 2027. Last updated on ClinicalTrials.gov: December 18, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.